Balaxi Pharmaceuticals Limited

NSE BALAXI.NS

Balaxi Pharmaceuticals Limited Revenue for the year ending March 31, 2024: USD 28.93 M

Balaxi Pharmaceuticals Limited Revenue is USD 28.93 M for the year ending March 31, 2024, a -29.33% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Balaxi Pharmaceuticals Limited Revenue for the year ending March 31, 2023 was USD 40.93 M, a 11.25% change year over year.
Balaxi Pharmaceuticals Limited Revenue for the year ending March 31, 2022 was USD 36.80 M, a 16.47% change year over year.
Balaxi Pharmaceuticals Limited Revenue for the year ending March 31, 2021 was USD 31.59 M, a 421.73% change year over year.
Balaxi Pharmaceuticals Limited Revenue for the year ending March 31, 2020 was USD 6.06 M, a 209.52% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NSE: BALAXI.NS

Balaxi Pharmaceuticals Limited

CEO	Ashish Maheshwari
IPO Date	Dec. 2, 2015
Location	India
Headquarters	MAPS Towers
Employees	51
Sector	Consumer Staples
Industries Retail & Wholesale Pharmaceuticals

Description

Balaxi Ventures Ltd. engages in the wholesale trading of pharmaceuticals, food products, and hardware. The company is headquartered in Hyderabad, Telangana. The Company’s products include pharmaceuticals products, food products and builders’ hardware products. The company operates through the operating segment international wholesale trading. Its pharmaceutical formulations and builders’ hardware products are contract manufactured from manufacturing plants in India. The firm offers a range of food and biscuit products under the brand name YAP. Its subsidiaries include Balaxi Global DMCC.

Key trends

Past 5 years